IP Library Granted Patent US 9,149,450
Granted Patent B2
US 9,149,450 · App. 14/260,377 · Granted Oct 6, 2015

Ischemia/reperfusion protection compositions and methods of using

Inventors: Matthew T. Andrews (Duluth, MN); Lester R. Drewes (Duluth, MN); Greg Beilman (Richfield, MN)
Assignee: Regents of the University of Minnesota
A61K31/19A61K9/0019A61K31/12A61K31/404A61K31/4045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,149,450
App. No.
14/260,377
Granted
Oct 6, 2015
Kind
B2
Abstract

The invention provides for ischemia/reperfusion protection compositions having one or more ketone bodies and melatonin. The invention also provides for methods of using such compositions to reduce or prevent ischemia/reperfusion injury due to blood loss, stroke or cardiopulmonary arrest or surgery.

Claims (18)

1. A method for treating an individual who is experiencing or has experienced blood loss, comprising administering a composition to the individual, wherein the composition comprises about 2 M to about 6 M D-beta-hydroxybutyrate or a pharmaceutically acceptable salt thereof, about 25 mM to about 80 mM melatonin or a metabolite, precursor or analog thereof, and at least one solvent.

2. The method of claim 1 , wherein the individual is experiencing or has experienced a major hemorrhagic event.

3. The method of claim 1 , wherein said blood loss in said individual results in a systolic blood pressure of about 70 mm Hg or less.

4. The method of claim 1 , wherein said composition is administered at a volume of about 0.3 to about 2 milliliters (mls) per kilogram (kg) of weight of said individual.

5. The method of claim 1 , wherein said composition is administered intravenously.

6. The method of claim 1 , wherein said individual's StO 2 levels are less than 75%.

7. The method of claim 6 , wherein said administering results in said individual's StO 2 levels returning to greater than 75%.

8. The method of claim 6 , wherein said individual has been treated when the individual's StO 2 levels are greater than 75%.

9. The method of claim 1 , wherein said individual's lactate levels are greater than 2.1 mg/dl.

10. The method of claim 9 , wherein said administering results in said individuals lactate levels returning to less than 2.1 mg/dl.

11. The method of claim 9 , wherein said individual has been treated when the individual's lactate levels are less than 2.1 mg/dl.

12. The method of claim 1 , further comprising transfusing said individual with blood or plasma.

13. The method of claim 1 , wherein the at least one solvent is water.

14. The method of claim 13 , wherein the at least one solvent further comprises dimethyl sulfoxide (DMSO).

15. The method of claim 13 , wherein the at least one solvent further comprises ethanol.

16. The method of claim 13 , wherein the at least one solvent further comprises dimethylsulfone.

17. The method of claim 13 , wherein the at least one solvent further comprises dimethylformamide (DMF).

18. The method of claim 1 , wherein the at least one solvent comprises water and dimethyl sulfoxide (DMSO).

Assignments (2)
CONFIRMATORY LICENSE Recorded May 4, 2015
From: UNIVERSITY OF MINNESOTA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035572/0690 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 14, 2014
From: ANDREWS, MATTHEW T.; DREWES, LESTER R.; BEILMAN, GREG
To: REGENTS OF THE UNIVERSITY OF MINNESOTA
Reel/Frame 033304/0444 →
Continuity (4)
Continuation 12082526 · Apr 11, 2008
Provisional Application 61026321 · Feb 5, 2008
Provisional Application 60911460 · Apr 12, 2007
Related Publication 20140235690A1 · Aug 21, 2014